Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Eylea

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PURPOSE To investigate the effect of age on aflibercept (Eylea) response in macular edema secondary to treatment-naive diabetic… Expand
Is this relevant?
2019
2019
Purpose: Aflibercept (Eylea™, Regeneron) is supplied in single-use glass vials along with 1 cc polycarbonate syringes. We sought… Expand
Is this relevant?
2019
2019
Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor. 
Is this relevant?
2018
2018
Vascular endothelial growth factor (VEGF) is a key mediator in the development and progression of choroidal neovascularization… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
PurposeTo investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients… Expand
  • table 1
  • table 2
Is this relevant?
2017
2017
INTRODUCTION Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several… Expand
  • figure 1
  • figure 2
Is this relevant?
2016
2016
PURPOSE We determined the intraocular pharmacokinetic properties of intravitreally injected aflibercept (Eylea) in a rabbit model… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2016
2016
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Anti-VEGF Drugs Anti-VEGF drugs are used to treat retinal conditions such as the wet form of age-related macular degeneration… Expand
Is this relevant?
Review
2012
Review
2012
  • The Medical letter on drugs and therapeutics
  • 2012
  • Corpus ID: 44732742
 
Is this relevant?